×

收藏-健康網會員訪問記錄

網頁標題:
×

注冊健康網用戶

用 戶 名:
聯 系 人:
性  別:
密  碼:
重復密碼:
電子郵箱:
郵箱驗證碼:
固定電話:
傳  真:
手  機:
單位名稱:
通信地址:
首選欄目:
我已經認真閱讀并同意《健康網服務條款》
×

找回密碼

  • 1.選擇找回方式
  • 2.確認驗證信息
  • 3.修改密碼
  • 4.修改成功
  • 找回方式:
  • 用 戶 名:
  • 手機號碼:

 您現在位置:健康網-醫藥產業 >> 研究報告 >> English reports >> English reports >> 瀏覽醫藥行業研究報告

Market Report of Monoclonal Antibody Drugs in China (2022)

作者:leigy   來源:本站原創    點擊數:0    更新時間:2022-9-20 9:13:54

[關鍵字]: mAb PD-1 ADC BsAb CTLA-4 DS-8201 BeiGene RemeGen Akeso TopAlliance Innovent Henlius Pembrolizumab "Keytruda"

健康網訊:

  Report Title: Market Report of Monoclonal Antibody Drugs in China (2022)

  date: Sep, 2022

  Format:  Adobe PDF

  Price:  $ 9,900

        ¥ 61,800

  Contact: Leo. (Mr. Lei Guangyu) / Ms. Xue zhe

  Tel: 86-10-68012929-2103/2113

  Mobile: 86-13810934380

  E-mail: leigy@healthoo.com


Monoclonal Antibody(mAb) drugs is the largest category of products in the biopharmaceutical industry. This report makes detailed statistics
analysis on the scale growth rate of domestic market, sales volume price trends, competitions, etc. of mAb in various treatment fields and 
different target categories in the past five years.

In recent years, the development marketing of monoclonal antibody drugs have increased rapidly. The number of monoclonal antibody drugs approved in China has increased from 13 in 2017 to 60 in 2022.

image.png

Graph 2 Number of mAB drugs listed in China from 2017 to July 2022

At present, monoclonal antibodies are mainly used in ten therapeutic fields, of which 33 are used for anti-tumor, 15 for rheumatoid other

autoimmune diseases, 3 for fundus maculopathy 2 for cholesterol lowering.

Table 4 Number of mAB drugs listed in China distribution of treatment fields from 2017 to July 2022

image.png

Monoclonal antibody drugs used in the field of anti-tumor therapy can be classified into four categories based on their mechanism of action market characteristics. One category is the traditional drugs targeting tumor related molecules, which can be classified into two sub 
categories: inhibiting the key molecules of tumor survival, activating the innate adaptive immunity against tumors. The other three are the 
most popular categories in recent years: immune checkpoint inhibitors, ADC (Antibody-drug conjugates) Bispecific antibody(BsAb) drugs. 

Table 8 Number of mAB for anti-tumor in China from 2017 to July 2022

image.png

Brentuximab Vedotin for injection is a mAB against CD38. It is the world's first ADC drug developed by Seagen Takeda in 2011. Its brname is “Adcetris”. It is sold by Takeda outside North America.

In 2020, Brentuximab vedotin imported into China for the treatment of lymphoma, which is the most successful commercial ADC drug in the 
field of blood tumor treatment. The specification is 50mg, the price decreased from 22,362 yuan/piece in 2020 to 16,860 yuan in 2021.

However, the negotiation of medical insurance has not been successful.


image.png

Graph 19 Sales volume price comparison of Brentuximab Vedotin for injection from 2020 to 2021

image.png

image.png

image.png

image.png

image.png

image.png

image.png

image.png

image.png

Market Report of Monoclonal Antibody Drugs in China (2022)
注冊后,我們會為你提供報告樣本并為您提供更全面的咨詢服務
您的姓名  稱謂: 先生女士
手機號碼 
電子郵件 
單位名稱 

服務熱線

  • 聯系項目:86-10-68012929-2103
  • 訂購報告:86-10-68012929-2103
  • 郵件訂購:leigy@healthoo.com
2020无码人妻视频中文字幕在线 91超碰碰碰碰久久久久久综合 日韩欧美一区二区三区中文精品 中文字幕人妻无码一区二区三区